이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Amylyx Pharmaceuticals 관리
관리 기준 확인 2/4
Amylyx Pharmaceuticals' CEO는 Josh Cohen, Jan2013 에 임명되었습니다 의 임기는 11.42 년입니다. 총 연간 보상은 $ 7.42M, 8.4% 로 구성됩니다. 8.4% 급여 및 91.6% 보너스(회사 주식 및 옵션 포함). 는 $ 4.57M 가치에 해당하는 회사 주식의 4.15% 직접 소유합니다. 4.57M. 경영진과 이사회의 평균 재임 기간은 각각 3.5 년과 3.4 년입니다.
주요 정보
Josh Cohen
최고 경영자
US$7.4m
총 보상
| CEO 급여 비율 | 8.4% |
| CEO 임기 | 11.5yrs |
| CEO 소유권 | 4.1% |
| 경영진 평균 재임 기간 | 3.5yrs |
| 이사회 평균 재임 기간 | 3.5yrs |
최근 관리 업데이트
Recent updates
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Jun 25Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop
Apr 25
Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically
Mar 12An ALS Drug Fails Again
Mar 09Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications
Feb 23Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues
Feb 23Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper
Nov 10Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Sep 24This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year
May 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Apr 20Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates
Mar 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans
Dec 19Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share
Oct 07Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis
Sep 30Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing
Sep 08Amylyx plunges 28% after FDA briefing documents on ALS drug
Sep 02We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
Aug 29Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01
Aug 11Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada
Jul 29Amylyx partners with Sunnybrook Research to identify neurodegenerative disease candidates
Jul 18Amylyx: Thoughts Ahead Of September 29 PDUFA In Amyotrophic Lateral Sclerosis
Jul 04Amylyx Pharmaceuticals: Share Price Bump On Canada Approval For ALS Drug May Not Last
Jun 17We're Keeping An Eye On Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
May 07Amylyx: Crucial Advisory Committee Meet Tomorrow, Approval Chancy
Mar 29CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$71m |
| Dec 31 2023 | US$7m | US$621k | US$49m |
| Sep 30 2023 | n/a | n/a | US$2m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$149m |
| Dec 31 2022 | US$7m | US$539k | -US$198m |
| Sep 30 2022 | n/a | n/a | -US$184m |
| Jun 30 2022 | n/a | n/a | -US$153m |
| Mar 31 2022 | n/a | n/a | -US$121m |
| Dec 31 2021 | US$1m | US$418k | -US$88m |
| Sep 30 2021 | n/a | n/a | -US$68m |
| Dec 31 2020 | US$671k | US$370k | -US$42m |
보상 대 시장: Josh 의 총 보상 ($USD 7.42M )은 US 시장( $USD 683.56K ).
보상과 수익: 회사가 수익성이 없는 동안 Josh 의 보상이 증가했습니다.
CEO
Josh Cohen (32 yo)
11.5yrs
테뉴어
US$7,418,169
보상
Mr. Joshua B. Cohen also known as Josh, co-founded Amylyx Pharmaceuticals, Inc. in 2013 and has been its Co-Chief Executive Officer and Director since January 2014. Mr. Cohen served as Chairman of the Boar...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Co-Founder | 11.5yrs | US$7.42m | 4.15% $ 5.0m | |
| Co-Founder | 11.5yrs | US$7.42m | 4.04% $ 4.9m | |
| Chief Financial Officer | 3.5yrs | US$3.51m | 0.13% $ 157.9k | |
| Chief Legal Officer & General Counsel | 2.4yrs | US$3.01m | 0% $ 0 | |
| Chief Medical Officer | less than a year | US$2.37m | 데이터 없음 | |
| Chief Technical Operations Officer | no data | 데이터 없음 | 데이터 없음 | |
| Head of Investor Relations & Communications | no data | 데이터 없음 | 데이터 없음 | |
| Head of Global Marketing | 3.6yrs | 데이터 없음 | 데이터 없음 | |
| Chief Human Resources Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Head of Canada & GM | 3.3yrs | 데이터 없음 | 데이터 없음 | |
| Head of Global Market Access | 3.6yrs | 데이터 없음 | 데이터 없음 | |
| Global Head of Regulatory Affairs | 3.9yrs | 데이터 없음 | 데이터 없음 |
3.5yrs
평균 재임 기간
53yo
평균 연령
경험이 풍부한 관리: AMLX 의 관리팀은 경험 ( 3.5 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Co-Founder | 10.5yrs | US$7.42m | 4.15% $ 5.0m | |
| Co-Founder | 10.5yrs | US$7.42m | 4.04% $ 4.9m | |
| Company Secretary & Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Special Advisor & Member of Advisory Board | 3.5yrs | US$51.24k | 데이터 없음 | |
| Independent Chairman of the Board | 9.5yrs | US$385.07k | 1.03% $ 1.2m | |
| Chairman of The Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Board Observer & Advisor | 7yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 1.3yrs | US$681.15k | 0% $ 0 | |
| Independent Director | 3.1yrs | US$348.59k | 0.0073% $ 8.8k | |
| Independent Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 3.3yrs | US$342.12k | 0.0058% $ 7.0k |
3.5yrs
평균 재임 기간
63yo
평균 연령
경험이 풍부한 이사회: AMLX 의 이사회는 경험(평균 재직 기간 3.4 년)으로 간주됩니다.